Company
ICON plc (Top 3 Global CRO)
Scope
Enterprise CRO Platform Deployment
Portfolio
200+ active compounds across 50+ sponsor companies
Challenge
Scalable, multi-sponsor BRA platform for CRO operations
ArcaScience Modules Used
Data Intelligence, Decision Intelligence, Automated Outputs
Timeline
16-week platform implementation
The Challenge
Scaling BRA Services Across a Diverse Multi-Sponsor Portfolio
As a leading CRO managing pharmacovigilance for 50+ sponsor companies, ICON faced unique challenges in delivering consistent, high-quality BRA across a diverse portfolio. Each sponsor had different data formats, safety database systems, and reporting requirements. Manual BRA preparation required extensive customization for each sponsor, limiting scalability.
The specific challenges facing ICON's pharmacovigilance operations were significant:
- Consultant time allocation: ICON's PV consultants spent 65% of their time on data preparation rather than scientific analysis, limiting the value they could deliver to sponsors
- Competitive pressure: Other CROs were investing in technology-driven differentiation, demanding faster turnaround and more advanced analytical capabilities
- Inconsistent quality: The lack of a standardized platform meant quality and timelines varied significantly across engagements, with consistency scores ranging from 60% to 90%
- Scalability constraints: Manual, consultant-dependent processes could not scale to meet growing demand without proportional headcount increases
- Sponsor onboarding delays: Integrating a new sponsor's data systems and processes took 4–6 weeks, slowing revenue recognition and client satisfaction
The Solution
ArcaScience Multi-Tenant BRA Platform
ArcaScience partnered with ICON to deploy a multi-tenant BRA platform capable of serving 50+ sponsor companies simultaneously, with configurable workflows that adapt to each sponsor's specific requirements while maintaining consistent quality standards.
Implementation Process
Weeks 1–3
Platform Architecture
Designed multi-tenant architecture with sponsor-specific data isolation. Mapped integration requirements for 8 major safety database systems (Argus, ArisGlobal, ARIS-g, etc.). Defined configurable workflow templates.
Weeks 4–7
Multi-Tenant Build
Built automated sponsor onboarding pipeline. Configured data connectors for each sponsor's safety database system. Created parameterized BRA templates for 12 therapeutic areas.
Weeks 8–11
Pilot Deployment
Launched with 25 sponsor compounds across oncology, immunology, and CNS. Validated output quality with sponsor PV teams. Refined AI models based on therapeutic area-specific requirements.
Weeks 12–14
Scale-Up
Extended to 200+ compounds across all therapeutic areas. Onboarded remaining 25+ sponsors. Integrated with ICON's existing regulatory submission workflows.
Weeks 15–16
Optimization & Training
Fine-tuned automation for compound-specific requirements. Trained 85+ ICON PV consultants on platform usage. Established SLAs and quality metrics.
Results
73%
Reduction in BRA
setup time
setup time
$8.4M
Annual operational
savings
savings
200+
Compounds on
platform
platform
50+ sponsors served simultaneously on a single platform
Quantitative Outcomes
| Metric | Before ArcaScience | After ArcaScience |
|---|---|---|
| BRA setup time per compound | 3–4 weeks | 3–5 days (73% reduction) |
| Compounds managed | 200+ (manually) | 200+ (automated platform) |
| PV consultant time on data prep | 65% | 20% |
| Sponsor onboarding time | 4–6 weeks | 5–7 days |
| BRA consistency score | Variable (60–90%) | Standardized (95%+) |
| Annual operational savings | Baseline | $8.4M |
"ArcaScience has become a core differentiator for ICON's pharmacovigilance services. Our ability to offer AI-powered benefit-risk analysis at scale, across any therapeutic area and any sponsor's data system, has transformed our competitive position. Sponsors are choosing ICON specifically because of this capability."
— EVP, Drug Safety & Pharmacovigilance, ICON plc
"The impact on our consultants has been transformative. Instead of spending most of their time wrestling with data, they're now focused on scientific analysis and strategic safety advice. That's better for our team, better for our sponsors, and ultimately better for patients."
— SVP, PV Operations, ICON plc
Key Takeaways
- Multi-tenant BRA platforms enable CROs to deliver consistent, high-quality safety analysis across diverse sponsor portfolios at unprecedented scale.
- The 73% reduction in BRA setup time transforms CRO economics, enabling profitable growth without proportional headcount increases.
- Standardized quality scores (95%+) across all engagements eliminate the variability inherent in manual, consultant-dependent processes.
- Freeing PV consultants from data preparation allows CROs to offer higher-value strategic safety consulting services.
- Rapid sponsor onboarding (5–7 days vs. 4–6 weeks) creates competitive advantage and accelerates revenue recognition.
Ready to Transform Your Benefit-Risk Strategy?
Learn how ArcaScience can support your next regulatory submission with AI-driven benefit-risk analysis.